SEITZ CHRISTIAN

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …

The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that requi…